Search Within

Lindsey Elizabeth Roeker

Formats
  1. Meeting Abstract (80)
  2. Journal Article (41)
  3. Research Letter (11)
  4. Review (5)
  5. Editorial (4)
  6. Book Section (1)
Groups
  1. Department of Medicine (142)
  2. Hematologic Malignancies, Division of (142)
  3. Center for Hematologic Malignancies (108)
  4. Adult Leukemia (104)
  5. GME, Medicine (43)
  6. Graduate Medical Education (43)

More Groups

People
  1. Anthony Mato (94)
  2. Meghan Thompson (37)
  3. Andrew Zelenetz (34)
  4. Omar Abdel-Wahab (16)
  5. Mark Geyer (15)
  6. Colleen Dorsey (14)

More People

Years
  1. 2025 (11)
  2. 2024 (20)
  3. 2023 (24)
  4. 2022 (24)
  5. 2021 (21)
  6. 2020 (21)

More Years

Publications
  1. Blood (58)
  2. Leukemia and Lymphoma (11)
  3. Blood Advances (7)
  4. Clinical Lymphoma, Myeloma and Leukemia (7)
  5. American Journal of Hematology (6)
  6. British Journal of Haematology (6)

More Publications

Publishers
  1. American Society of Hematology (66)
  2. Taylor & Francis Group (11)
  3. Elsevier Inc. (8)
  4. John Wiley & Sons (7)
  5. American Association for Cancer Research (6)
  6. American Society of Clinical Oncology (6)

More Publishers

Results (142)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Tumor lysis, adverse events, and dose adjustments in 297 venetoclax-treated CLL patients in routine clinical practice
    Journal Article

    Roeker, L. E.; Fox, C. P.; Eyre, T. A.; Brander, D. M.; Allan, J. N.; Schuster, S. J.; Nabhan, C.; Hill, B. T.; Shah, N. N.; Lansigan, F.; more...
    Clinical Cancer Research (2019)

    Fulltext@MSK | Save
  • Hypertension (HTN) in patients (pts) treated with ibrutinib (IBR) for chronic lymphocytic leukemia (CLL)
    Meeting Abstract

    Sarraf Yazdy, M.; Roeker, L.; Gashonia, L.; Goodfriend, J.; Narkhede, M.; Rhodes, J.; Kennard, K.; Morse, H.; Dorsey, C.; Battiato, K.; more...
    Hematological Oncology (2019)

    Fulltext@MSK | Save
  • Phase I/II study of umbralisib (TGR‐1202) in combination with ublituximab (TG‐1101) and pembrolizumab in patients with REL/REF CLL and Richter's transformation
    Meeting Abstract

    Mato, A. R.; Svoboda, J.; Luning Prak, E. T.; Schuster, S. J.; Tsao, P. Y.; Dorsey, C.; Sarmasti, L. M.; Becker, P. S.; Brander, D. M.; Nasta, S.; more...
    Hematological Oncology (2019)

    Fulltext@MSK | Save
  • A retrospective comparison of venetoclax alone or in combination with an anti-CD20 monoclonal antibody in R/R CLL
    Journal Article

    Mato, A. R.; Roeker, L. E.; Eyre, T. A.; Nabhan, C.; Lamanna, N.; Hill, B. T.; Brander, D. M.; Barr, P. M.; Lansigan, F.; Cheson, B. D.; more...
    Blood Advances (2019)

    Fulltext@MSK | Save
  • Early clinical predictors of hepatic veno-occlusive disease/sinusoidal obstruction syndrome after myeloablative stem cell transplantation
    Journal Article

    Roeker, L. E.; Kim, H. T.; Glotzbecker, B.; Nageshwar, P.; Nikiforow, S.; Koreth, J.; Armand, P.; Cutler, C.; Alyea, E. P.; Antin, J. H.; more...
    Biology of Blood and Marrow Transplantation (2019)

    Fulltext@MSK | Save
  • Phase I/II study of umbralisib (TGR-1202) in combination with ublituximab (TG-1101) and pembrolizumab in patients with relapsed/refractory CLL and Richter's transformation
    Meeting Abstract

    Mato, A. R.; Svoboda, J.; Prak, E. T. L.; Schuster, S. J.; Tsao, P.; Dorsey, C.; Becker, P. S.; Brander, D. M.; Nasta, S. D.; Landsburg, D. J.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Real-world treatment patterns among a contemporary cohort of commercially insured mantle cell lymphoma patients in the United States
    Meeting Abstract

    Roeker, L. E.; Kabadi, S.; Burudpakdee, C.; Near, A.; Wada, K.; Mato, A. R.
    Blood (2018)

    Fulltext@MSK | Save
  • Venetoclax as monotherapy or in combination: Patterns of use and predictors of outcomes in an international multicenter study of CLL patients
    Meeting Abstract

    Mato, A. R.; Roeker, L. E.; Eyre, T. A.; Nabhan, C.; Lamanna, N.; Hill, B. T.; Brander, D. M.; Barr, P.; Lansigan, F.; Cheson, B.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Treatment patterns and outcomes of patients with CLL treated with chemoimmuno- and novel agent-based therapy: A multicenter study
    Meeting Abstract

    Mato, A. R.; Yazdy, M. S.; Hill, B. T.; Shadman, M.; Tuncer, H.; Winter, A. M.; Kennard, K.; Allan, J. N.; Ujjani, C. S.; Brander, D. M.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Evidence for and against green tea and turmeric in the management of chronic lymphocytic leukemia
    Journal Article

    Bange, E.; Timlin, C.; Kabel, C.; Svoboda, J.; Roeker, L.; Mato, A. R.
    Clinical Lymphoma, Myeloma and Leukemia (2018)

    Fulltext@MSK | Save